tetragastrin and Premenstrual-Syndrome

This study examined the effects of i.v. administration of cholecystokinin-tetrapeptide (CCK-4) on plasma release of arginine vasopressin (AVP) and oxytocin (OT) in women with premenstrual dysphoric disorder (PMDD) and control women, during both the follicular phase and the luteal phase of their menstrual cycle. Plasma AVP and OT concentrations increased following CCK-4 administration. AVP and OT response to CCK-4 was similar for PMDD and control women and unaffected by menstrual cycle phase. AVP and OT may play a role in the hypothalamo-pituitary adrenal (HPA) axis activity associated with the panic response induced by CCK-4.

Topics: Adult; Arginine Vasopressin; Cholecystokinin; Cross-Over Studies; Double-Blind Method; Female; Humans; Oxytocin; Panic Disorder; Peptides; Placebos; Premenstrual Syndrome; Radioimmunoassay; Tetragastrin; Time Factors; Vasoconstrictor Agents

The authors determined whether women with premenstrual dysphoric disorder (PMDD) exhibit a heightened sensitivity to the panicogenic effects of CCK-4 administration and whether this enhanced sensitivity to CCK-4 would vary with the phase of the menstrual cycle at the time of CCK-4 injection. Twenty-one normal controls and 18 PMDD women were randomly assigned to receive the first and second CCK-4 injection during the follicular phase and the luteal phase or vice versa. PMDD women showed a greater anxiety and panic response to CCK-4. These preliminary results suggest that the CCK-B system may play a role in the pathophysiology of PMDD.

Topics: Adult; Anxiety; Cross-Over Studies; Female; Follicular Phase; Hormones; Humans; Luteal Phase; Panic; Premenstrual Syndrome; Tetragastrin

Topics: Female; Humans; Menstrual Cycle; Panic Disorder; Placebos; Premenstrual Syndrome; Tetragastrin

Topics: Anxiety Disorders; Carbon Dioxide; Comorbidity; Depressive Disorder; Female; Humans; Lactates; Menstrual Cycle; Panic Disorder; Premenstrual Syndrome; Tetragastrin